GAO’s reports and testimonies give Congress, federal agencies, and the public timely, fact-based, non-partisan information that can improve government operations and save taxpayers billions of dollars.
Remdesivir was the first drug approved by the Food and Drug Administration to treat COVID-19. Gilead Sciences, Inc., originally developed it to treat other viral diseases.
We reviewed federal contributions to development of remdesivir and related agency patent rights.
As of Dec.
Genomic sequencing technology has the potential to improve how we monitor and treat infectious diseases. By revealing the genetic codes of pathogens, it can allow researchers to develop targeted vaccines, track new variants of the virus that causes COVID-19, and more.
How many people have COVID-19, and what will the pandemic look like in the future?
Forecasting models can help predict trends such as infection or mortality rates. But these models rely on data that is collected by different jurisdictions and reported under different standards.
E-cigarettes are battery-powered devices that generate an inhalable aerosol that usually contains nicotine. They are designed as alternatives to traditional cigarettes.
Millions of teens and young adults now use e-cigarettes.
Infectious disease models can help guide policy decisions, such as how to allocate health care resources in response to COVID-19. Interpreting them requires understanding their purpose, limitations, and assumptions.
How far is far enough for successful social distancing? We take a look at some of the still-developing science behind the practice.
A CDC guideline based on historical studies of selected infections says that the area of highest risk is within 3 feet of an infected person.
In 2015, the Department of Defense discovered that one of its labs had inadvertently sent live anthrax to almost 200 other labs worldwide over 12 years. The lab's "inactivation" (removal of hazardous effects) of the pathogen was incomplete.